T. Rowe Price Investment Management
KPTI icon

T. Rowe Price Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

T. Rowe Price Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68M Sell
786,309
-755,781
-49% -$6.56M 0.01% 632
2026
Q1 		$8.59M Buy
1,542,090
+50,681
+3% +$386K 0.01% 542
2025
Q4 		$11M Buy
1,491,409
+790,417
+113% +$4.83M 0.01% 547
2025
Q3 		$4.58M Sell
700,992
-27,774
-4% -$149K ﹤0.01% 576
2025
Q2 		$3.14M Buy
728,766
+589,120
+422% +$2.89M ﹤0.01% 589
2025
Q1 		$523K Buy
+139,646
New +$1.19M ﹤0.01% 633

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

T. Rowe Price Investment Management's KPTI Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Karyopharm Therapeutics (KPTI) stake by 49% in Q2 2026, selling an estimated $6.56M and leaving 786,309 shares worth $7.68M. The position accounts for 0.01% of the portfolio, ranked #632.

T. Rowe Price Investment Management first reported a position in KPTI in Q1 2025 and has held it in 6 quarters since. The position peaked at $11M in Q4 2025. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • T. Rowe Price Investment Management held 786,309 shares of Karyopharm Therapeutics worth $7.68M as of Q2 2026.
  • T. Rowe Price Investment Management sold 755,781 Karyopharm Therapeutics shares in Q2 2026, an estimated $6.56M.
  • Karyopharm Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #632 holding.
  • T. Rowe Price Investment Management first reported a position in Karyopharm Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • T. Rowe Price Investment Management's Karyopharm Therapeutics position peaked at $11M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.